FINNENCE▪
00:00:00 UTCSYS ONLINE
FINNENCE ▪ THE WIRE FILE

THE WIRE · № 68422

Video▲ Bullish

Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter

EXHIBIT · i2.ytimg.com
KINDVideo
DIRECTION▲ Bullish
SOURCES1
ENTITIES6
STORY SIZESTANDALONE
FIRST SEEN2026-10-06 22:17 UTC
LAST UPDATE2026-10-06 22:17 UTC
STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

Goldman's biotech analyst flags large pharma interest in China assets, implying licensing and M&A flows into Chinese biotech.

China biotech assets draw pharma deal interest
CATALYST TO WATCH

Announced licensing or acquisition deals

MAIN RISK

Deal interest may not convert to transactions

FULL DISPATCH

Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Closing Bell Overtime' to talk biotech innovations in China.

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED
№ 01youtubeyoutube.com · PRIMARY2026-10-06 22:17 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.